snIP/ITs Insights on Canadian Technology and Intellectual Property Law

Tag Archives: Competition Bureau

Fintech Regulatory Developments: 2017 Year in Review

Posted in Fintech, Regulatory Compliance

As predicted in our 2016 year-end report, 2017 proved to be a busy year for Fintech in Canada, with a number of important regulatory developments. With the dawn of 2018, we look back to summarize some of 2017’s most notable Fintech regulatory developments in Canada, as well as developments to watch for in 2018.… Continue Reading

Canada’s Competition Commissioner Emphasizes Innovation, Highlights Fintech Market Study

Posted in Fintech

Canada’s Commissioner of Competition, John Pecman, spoke on October 6th, 2016 to the Canadian Bar Association’s Competition Law Fall Conference, addressing the link between competition and innovation and providing updates on the Fintech market study launched by the Competition Bureau earlier this year.Continue Reading

Competition Bureau to Study Fintech Market

Posted in Fintech, Regulatory Compliance

The Competition Bureau announced on May 19, 2016 that it will launch a market study focused on how innovation in the fintech sector is impacting consumers and businesses, with the results intended to be published in the spring of 2017, seeking to determine whether there is a need for “regulatory reform to promote greater competition while maintaining consumer confidence in the sector.”

The announcement cites a report indicating that Canada appears to be lagging other countries in adoption of fintech as one of the reasons for deciding to study the financial services industry.… Continue Reading

Competition Bureau Finalizes IP Enforcement Guidelines on ‘Pay-for-Delay’ Settlements, Pharmaceutical Product Switching, and ‘Patent Trolls’

Posted in Consumer Protection, Intellectual Property, Patents, Regulatory Compliance

On March 31, 2016, the Competition Bureau (Bureau) released revised Intellectual Property Enforcement Guidelines (IPEGs). These IPEGs reflect incremental changes to the draft version released for consultation last year. Most notably the new IPEGs provide further guidance on (i) pharmaceutical patent litigation settlements, (ii) product switching (also known as “product hopping”), (iii) collaborative standard setting and standard essential patents, and (iv) patent assertion entities.… Continue Reading